Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Leukemia & Lymphoma|May 10, 2002
Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cellsKai U Chow, Simone Boehrer, Joerg Bojunga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancerSalah-Eddin Al-Batran, Akin Atmaca, Susanna Hegewisch-Becker, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 1999
Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapseM J Rummel, K U Chow, E Jäger, et al.Leukemia & Lymphoma|April 28, 2000
Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantroneK U Chow, M J Rummel, E Weidmann, et al.Leukemia & Lymphoma|October 8, 1999
Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomasM J Rummel, K U Chow, E Jäger, et al.Haematologica|March 30, 2019
Glycoprotein V is a relevant immune target in patients with immune thrombocytopeniaRichard Vollenberg, Rabie Jouni, Peter A A Norris, et al.European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphomaM J Rummel, K U Chow, T Karakas, et al.Onkologie|July 7, 2001
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicineE Weidmann, S Boehrer, K U Chow, et al.Leukemia|August 16, 2022
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphomaMathias J Rummel, Salah E Al-Batran, Soo-Z Kim, et al.Pageof 5